Benzinga
Benzinga
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Benzinga
dimanche, octobre 18
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Krystal Biotech Inc
KRYS
NASDAQ
Liste de surveillance
Get Report
Trade with Public
Get Report
Trade with Public
$316.58
-13.42
-4.07%
Dern. MÀJ: Oct 16, 4:00 PM
$316.58
-13.42
-4.07%
Get Report
Aperçu
Actualités
Prévisions de résultats
Événements
Objectifs de cours
Données financières
Sentiment
Actionnariat
Comparer
Options
Rapport sur les stocks
Privacy Manager
Krystal Biotech Financials
Krystal Biotech (KRYS) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Krystal Biotech Q2 EPS $1.79 Beats $1.66 Estimate, Sales $119.222M Miss $121.061M Estimate
Krystal Biotech (NASDAQ:KRYS) reported quarterly earnings of $1.79 per share which beat the analyst consensus estimate of $1.66 by 7.83 percent. This is a 38.76 percent increase over earnings of $1.29 per share from the
Benzinga Newsdesk
Krystal Biotech Analysts Boost Their Forecasts Following Upbeat Q1 Results
Krystal Biotech (KRYS) reported strong Q1 earnings, beating analyst estimates and with potential for future growth. Shares fell 1% on Tuesday.
Avi Kapoor
Earnings Scheduled For May 4, 2026
Benzinga Insights
PRO
Krystal Biotech Q1 EPS $1.83 Beats $1.39 Estimate, Sales $116.357M Beat $112.132M Estimate
Krystal Biotech (NASDAQ:KRYS) reported quarterly earnings of $1.83 per share which beat the analyst consensus estimate of $1.39 by 31.65 percent. This is a 52.5 percent increase over earnings of $1.20 per share from the
Benzinga Newsdesk
Krystal Biotech: Q4 Earnings Insights
Benzinga Insights
PRO
Krystal Biotech Q4 EPS $1.70 Beats $1.39 Estimate, Sales $107.105M Beat $105.338M Estimate
Krystal Biotech (NASDAQ:KRYS) reported quarterly earnings of $1.70 per share which beat the analyst consensus estimate of $1.39 by 22.21 percent. This is a 11.84 percent increase over earnings of $1.52 per share from the
Benzinga Newsdesk
